Earnings Call · Q4 FY2022·2023-03-01

Q4 22EPS 0.00%·Rev n/aQ3 22EPS +1.56%·Rev n/aQ2 22EPS -3.28%·Rev n/aQ1 22EPS +7.94%·Rev n/a⚠ consensus missing

IOVANCE BIOTHERAPEUTICS, INC. IOVA

Sara Pellegrino — Investor Relations or Corporate Communications

Fred Vogt — Interim President and Chief Executive Officer

Igor Bilinsky — Chief Operating Officer

Jim Ziegler — Executive Vice President, Commercial

Friedrich Finckenstein — Chief Medical Officer

Jean-Marc Bellemin — Chief Financial Officer

+0.1%1d on move date+0.5% vs SPY3d+0.8%5d−1.2%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more IOVA calls or request research access.

More IOVA calls Browse calls Request research access